Product Description
Mechanisms of Action: RTK Inhibitor, C-Met Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: Eastern America
Company Founding Year: 1989
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer
Phase 1: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|Healthy Volunteers|Oncology Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00697632 |
NCT00697632 | P1 |
Completed |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Head and Neck Cancer|Squamous Cell Carcinoma |
2018-09-01 |
18% |
2019-03-22 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
NCT01930006 |
NCT01930006 | P1 |
Completed |
Healthy Volunteers|Oncology Unspecified |
2013-12-01 |
2019-03-19 |
Treatments |
|
NCT00975767 |
NCT00975767 | P1 |
Terminated |
Non-Small-Cell Lung Cancer |
2013-07-01 |
2025-08-27 |
Primary Endpoints|Treatments |
|
NCT00679133 |
NCT00679133 | P1 |
Completed |
Oncology Unspecified |
2011-03-01 |
2019-03-18 |
Treatments |
|
NCT02954991 |
MRTX-500 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2021-11-04 |
43% |
2024-04-23 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
2015-002070-21 |
2015-002070-21 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2019-01-02 |
2022-03-13 |
Treatments |
|
NCT02544633 |
NCT02544633 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2018-04-30 |
12% |
2019-03-22 |